A former critic of FDA and Pharma will now oversee the regulation of costly and complicated biologics like vaccines, gene therapies, and blood supply.

From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...

FDA commissioner Marty Makary told FDA staff in an email that Prasad, “brings a great set of skills, energy, and competence ...

Viatris faces tariff pressures, FDA concerns, and geopolitical risks despite some pipeline promise and stable guidance. Read ...

The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...

During his first term, attempts by President Donald Trump to slash drug price | After failing in his first term to install a ...

The independent experts will meet on May 22 to discuss updates to the COVID-19 vaccine for the upcoming season.

The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval ...

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...

Compounding pharmacies suffered another blow yesterday, as a federal judge sided with the FDA over its decision last year to ...